-
Published26/05/2025
-
Today19/06/2025
-
Deadline21/05/2027
-
Opening of tenders21/05/2027
Utilities
- indicates text translated automatically in your browsing language
Medicinal discount contracts pursuant to § 130a (8c) SGB V from 01.08.2025 on various active substances in the context of an open-house procedure Text automatically translated in your browsing language Automatically translated
The subject of this publication is the conclusion of non-exclusive discount agreements pursuant to § 130a(8c) SGB V for parenteral preparations made in pharmacies from finished medicinal products in oncology for direct medical use in patients for the regions of North Rhine-Westphalia, Hamburg and Schleswig-Holstein. The non-exclusive discount agreements are offered for regional lots 1 (North Rhine-Westphalia), 2 (Hamburg), 3 (Schleswig-Holstein) for the following active substances: Bevacizumab (L01FG01) Eribulin (L01XX41) Rituximab (L01FA01) Trastuzumab (L01FD01) The earliest contract start date is 01.08.2025. On this basis, the contract term is a maximum of 24 months. Text automatically translated in your browsing language Automatically translated
sen-info
IKK - Die Innovationskasse
DAK-Gesundheit
BKK Landesverband NORDWEST
Kaufmännische Krankenkasse - KKH
HEK - Hanseatische Krankenkasse
KNAPPSCHAFT
AOK Rheinland/Hamburg - Die Gesundheitskasse
IKK classic
Techniker Krankenkasse (TK)
Handelskrankenkasse (hkk), Bremen
Sozialversicherung für Landwirtschaft, Forsten und Gartenbau (SVLFG) als Landwirtschaftliche Krankenkasse (LKK)
This content published on this page is meant purely as an additional service and has no legal effect. The Union's institutions do not assume any liability for its contents. The official versions of the relevant tendering notices are those published in the Supplement of Official Journal of the European Union and available in TED. Those official texts are directly accessible through the links embedded in this page. For more information please see Public Procurement Explainability and Liability notice.